NCT02010021View on ClinicalTrials.gov

Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 8, 2017

Study Completion Date

December 8, 2017

Conditions
Breast Cancer
Interventions
DRUG

Letrozole

Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.

Trial Locations (1)

03756

Dartmouth Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT02010021 - Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer. | Biotech Hunter | Biotech Hunter